Magnetic resonance elastography to quantify liver disease severity in autosomal recessive polycystic kidney disease.

TitleMagnetic resonance elastography to quantify liver disease severity in autosomal recessive polycystic kidney disease.
Publication TypeJournal Article
Year of Publication2020
AuthorsHartung EA, Calle-Toro JS, Lopera CMaya, Wen J, Carson RH, Dutt M, Howarth K, Furth SL, Darge K, Serai SD
JournalAbdom Radiol (NY)
Date Published2020 Aug 05
ISSN2366-0058
Abstract

OBJECTIVES: To evaluate whether liver and spleen magnetic resonance elastography (MRE) can measure the severity of congenital hepatic fibrosis (CHF) and portal hypertension (pHTN) in individuals with autosomal recessive polycystic kidney disease (ARPKD), and to examine correlations between liver MRE and ultrasound (US) elastography.

METHODS: Cross-sectional study of nine individuals with ARPKD and 14 healthy controls. MRE was performed to measure mean liver and spleen stiffness (kPa); US elastography was performed to measure point shear wave speed (SWS) in both liver lobes. We compared: (1) MRE liver and spleen stiffness between controls vs. ARPKD; and (2) MRE liver stiffness between participants with ARPKD without vs. with pHTN, and examined correlations between MRE liver stiffness, spleen length, platelet counts, and US elastography SWS. Receiver operating characteristic (ROC) analysis was performed to examine diagnostic accuracy of liver MRE.

RESULTS: Participants with ARPKD (median age 16.8 [IQR 13.3, 18.9] years) had higher median MRE liver stiffness than controls (median age 14.7 [IQR 9.7, 16.7 years) (2.55 vs. 1.92 kPa, p = 0.008), but MRE spleen stiffness did not differ. ARPKD participants with pHTN had higher median MRE liver stiffness than those without (3.60 kPa vs 2.49 kPa, p = 0.05). Liver MRE and US elastography measurements were strongly correlated. To distinguish ARPKD vs. control groups, liver MRE had 78% sensitivity and 93% specificity at a proposed cut-off of 2.48 kPa [ROC area 0.83 (95% CI 0.63-1.00)].

CONCLUSION: Liver MRE may be a useful quantitative method to measure the severity of CHF and pHTN in individuals with ARPKD.

DOI10.1007/s00261-020-02694-1
Alternate JournalAbdom Radiol (NY)
PubMed ID32757071
Grant ListK23-DK109203 / DK / NIDDK NIH HHS / United States
KL2-TR-000139 / TR / NCATS NIH HHS / United States
UL1TR000003 / TR / NCATS NIH HHS / United States
UL1TR001878 / TR / NCATS NIH HHS / United States
UL1RR024134 / RR / NCRR NIH HHS / United States